Somapacitan

Mechanism

A game-changer for growth hormone therapy — the first once-weekly GH approved by the FDA. It's a modified GH molecule that sticks to albumin in your blood, slowing its clearance from ~2 hours to about a week. Patients get one injection per week instead of seven, with equivalent results. The REAL 4 trial confirmed it works just as well as daily GH injections.

Effects

ENDOCRINE SYSTEM: Somapacitan (Sogroya) is a long-acting growth hormone analog designed for once-weekly subcutaneous injection. It is a modified GH molecule with a single amino acid substitution (L101C) and an albumin-binding moiety (a C16 fatty diacid attached via a linker) that enables reversible binding to circulating albumin. This albumin binding protects somapacitan from renal clearance and proteolytic degradation, extending the half-life to approximately 160 hours (~2-3 days of active GH exposure after each weekly injection) compared to somatropin's 2-3 hour half-life. The molecule retains full GH receptor agonist activity — it binds and activates the GH receptor identically to native GH, stimulating hepatic IGF-1 production, lipolysis, protein synthesis, and linear growth [RCT — REAL trials]. GROWTH AND BODY COMPOSITION: In pediatric GHD, somapacitan demonstrated non-inferior annualized height velocity compared to daily Norditropin (11.2 vs. 11.7 cm/year in the REAL 4 trial) with comparable IGF-1 normalization [RCT]. In adult GHD, the REAL 1 trial showed significant reduction in trunk fat percentage vs. placebo (-1.06%), with IGF-1 normalization and improved body composition comparable to daily GH [RCT]. Quality-of-life scores improved in adults switching from daily GH to weekly somapacitan, driven primarily by reduced injection burden. PHARMACOKINETIC PROFILE: After weekly SC injection, somapacitan shows a gradual absorption phase (Tmax ~18-22 hours), followed by sustained GH activity over 3-4 days, then tapering. This creates a profile with higher peak-to-trough variability compared to daily injections — IGF-1 levels fluctuate more within the week (peak around day 2-3, trough before next injection). Clinical significance of this fluctuation is debated: some argue it could be advantageous (mimicking pulsatility more than daily injections) while others note it differs from the natural ultradian GH pulse pattern. The albumin-binding mechanism means hypoalbuminemic patients (liver disease, nephrotic syndrome) may have altered pharmacokinetics. SAFETY PROFILE: Side effects are consistent with GH class effects — injection site reactions (mild, transient), headache, arthralgia, peripheral edema, nasopharyngitis. No unique safety signals beyond what is seen with daily somatropin. Anti-drug antibodies developed in a small percentage of patients but were non-neutralizing and did not affect efficacy. Lipodystrophy at injection sites was uncommon. Insulin resistance and glucose effects comparable to daily GH. Long-term safety data is still accumulating but appears reassuring through 3+ years of follow-up in open-label extensions.

Practitioner Guide

DOSING: Adults — start at 1.5 mg SC once weekly, titrate by 0.5-1.5 mg every 2-4 weeks based on IGF-1 levels (target: age-appropriate normal range, similar to daily GH targets). Maintenance range typically 1-8 mg/week. Women on oral estrogen may require higher doses. Pediatric GHD: 0.16 mg/kg/week SC (FDA-approved in US for pediatric GHD since 2023). Inject on the same day each week, any time of day. If a dose is missed by <3 days, take it when remembered; if >3 days, skip and resume on the regular schedule. ADMINISTRATION: Prefilled pen devices (similar to Norditropin FlexPro). Store refrigerated; can be at room temperature for up to 6 weeks after first use. Inject SC into abdomen, thigh, or upper arm. Rotate injection sites within the same body region. MONITORING: Same as daily GH — IGF-1 levels, fasting glucose, HbA1c, free T4, morning cortisol, lipids. Key difference: draw IGF-1 levels 3-4 days after injection (near the peak) to get a representative level. Some practitioners check trough IGF-1 (day 7, just before next injection) as well to assess the full weekly profile. During titration, check IGF-1 every 4 weeks. Once stable, every 6-12 months. TRANSITIONING FROM DAILY GH: Multiply the total weekly dose of daily somatropin by approximately 7 to get the starting weekly somapacitan dose, then adjust based on IGF-1 response. Example: patient on 0.4 mg/day somatropin = 2.8 mg/week → start somapacitan ~3 mg/week and titrate. CLINICAL POSITIONING — WHO BENEFITS MOST: Weekly GH is a game-changer for adherence. Daily GH injections have notoriously poor long-term adherence — studies show 50-70% of pediatric patients miss >1 injection per week, and adult adherence drops significantly after year 1. Somapacitan is ideal for: pediatric patients and families fatigued by daily injections, adults with injection aversion, travelers, busy professionals, anyone who has demonstrated poor daily adherence. COMPARISON TO DAILY GH: Efficacy is equivalent — the convenience is the differentiator. Cost is higher per injection but comparable when accounting for adherence benefits. COMPARISON TO SECRETAGOGUES: Somapacitan delivers exogenous GH (non-pulsatile), whereas secretagogues stimulate endogenous pulsatile release. For true GHD, somapacitan is superior (secretagogues require a functional pituitary). For optimization in non-GHD populations, secretagogues remain the more physiological approach. COMPARISON TO LONAPEGSOMATROPIN: Both are weekly GH, but different mechanisms — somapacitan is a modified GH analog (albumin binding), while lonapegsomatropin is a prodrug that releases unmodified native GH. Theoretically, lonapegsomatropin may better replicate native GH biology since the released molecule is identical to endogenous GH.

Evidence

• Utilizing Somapacitan, a Long-acting Growth Hormone Formulation, for the Treatment of Adult Growth Hormone Deficiency: A Guide for Clinicians

  Kevin C J Yuen (2024) — Endocr Pract — PMID: 38992799

  Review concludes somapacitan, a once-weekly reversible albumin-binding GH derivative, improves truncal and visceral fat, lean body mass, and IGF-1 targets in adult GHD with neutral glucose effects, comparable adverse events to daily GH, and higher treatment satisfaction.

  moderate

Research Summary

TIER 1: REAL 1 trial (2020, Johannsson et al.) — Phase III RCT in adult GHD: somapacitan vs. placebo and daily Norditropin. Significant trunk fat reduction, IGF-1 normalization, non-inferior to daily GH. REAL 3 trial (2022) — Phase III in treatment-naive adult GHD: confirmed efficacy vs. placebo. REAL 4 trial (2022, Engelen et al.) — Phase III in pediatric GHD: non-inferior height velocity vs. daily Norditropin at 52 weeks (11.2 vs. 11.7 cm/year). FDA approved for adult GHD (2020, brand name Sogroya) and pediatric GHD (2023). EMA approved for adult GHD (2021). Open-label extension data through 3+ years showing sustained efficacy and safety. TIER 2: Pharmacokinetic modeling studies characterizing the albumin-binding mechanism and weekly IGF-1 fluctuation profiles. Post-hoc analyses of REAL trials examining subgroups (gender, age, prior treatment). Health economic analyses showing cost-effectiveness driven by improved adherence. Systematic reviews comparing all long-acting GH formulations (somapacitan, lonapegsomatropin, somatrogon). TIER 3: Real-world registry data from early adopters (primarily Scandinavian centers). Expert opinion pieces on the role of weekly GH in clinical practice. Patient preference studies showing strong preference for weekly over daily injections (unsurprisingly). KEY FINDINGS: Somapacitan delivers on the promise of effective once-weekly GH with a well-characterized safety profile. Efficacy is genuinely non-inferior to daily GH. The main value proposition is adherence and patient convenience — not superior efficacy. The albumin-binding technology is elegant and well-proven (similar to semaglutide and insulin degludec from Novo Nordisk). GAPS: No head-to-head RCT against lonapegsomatropin. Limited data in non-GHD populations (anti-aging use would be off-label). Very long-term safety (10+ years) not yet available. Pharmacokinetics in special populations (liver disease, renal impairment, obesity) need further characterization. ACTIVE TRIALS: Ongoing open-label extensions of REAL trials. Additional pediatric indications under investigation (Turner syndrome, SGA, Prader-Willi). Phase III in Japan and China.